hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/109039
Title:
hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.
Authors:
Gee, Harriet E; Camps, Carme; Buffa, Francesca M; Patiar, Shalini; Winter, Stuart C; Betts, Guy N J; Homer, Jarrod J; Corbridge, Rogan J; Cox, Graham J; West, Catharine M L; Ragoussis, Jiannis; Harris, Adrian L
Abstract:
BACKGROUND: Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis. METHODS: Three hypoxia-related microRNAs, hsa-miR-210, hsa-miR-21, and hsa-miR-10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99-gene hypoxia metagene, individual hypoxia-related genes such as TWIST1, and immunohistochemical expression of hypoxia-inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs. RESULTS: Only the level of hsa-miR-210 was significantly correlated with other markers of hypoxia, including the 99-gene hypoxia metagene (rho = 0.67, P < .001). We found no association between hsa-miR-210, hsa-miR-21, or hsa-miR-10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa-miR-210 were associated with locoregional disease recurrence (P = .001) and short overall survival (P = .008). hsa-miR-21 and hsa-miR-10b had no prognostic significance. CONCLUSIONS: Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia.
Affiliation:
Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Citation:
hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. 2010, 116 (9):2148-58 Cancer
Journal:
Cancer
Issue Date:
1-May-2010
URI:
http://hdl.handle.net/10541/109039
DOI:
10.1002/cncr.25009
PubMed ID:
20187102
Type:
Article
Language:
en
ISSN:
0008-543X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGee, Harriet Een
dc.contributor.authorCamps, Carmeen
dc.contributor.authorBuffa, Francesca Men
dc.contributor.authorPatiar, Shalinien
dc.contributor.authorWinter, Stuart Cen
dc.contributor.authorBetts, Guy N Jen
dc.contributor.authorHomer, Jarrod Jen
dc.contributor.authorCorbridge, Rogan Jen
dc.contributor.authorCox, Graham Jen
dc.contributor.authorWest, Catharine M Len
dc.contributor.authorRagoussis, Jiannisen
dc.contributor.authorHarris, Adrian Len
dc.date.accessioned2010-08-04T11:08:11Z-
dc.date.available2010-08-04T11:08:11Z-
dc.date.issued2010-05-01-
dc.identifier.citationhsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. 2010, 116 (9):2148-58 Canceren
dc.identifier.issn0008-543X-
dc.identifier.pmid20187102-
dc.identifier.doi10.1002/cncr.25009-
dc.identifier.urihttp://hdl.handle.net/10541/109039-
dc.description.abstractBACKGROUND: Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis. METHODS: Three hypoxia-related microRNAs, hsa-miR-210, hsa-miR-21, and hsa-miR-10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99-gene hypoxia metagene, individual hypoxia-related genes such as TWIST1, and immunohistochemical expression of hypoxia-inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs. RESULTS: Only the level of hsa-miR-210 was significantly correlated with other markers of hypoxia, including the 99-gene hypoxia metagene (rho = 0.67, P < .001). We found no association between hsa-miR-210, hsa-miR-21, or hsa-miR-10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa-miR-210 were associated with locoregional disease recurrence (P = .001) and short overall survival (P = .008). hsa-miR-21 and hsa-miR-10b had no prognostic significance. CONCLUSIONS: Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia.en
dc.language.isoenen
dc.subjectTumour Cell Lineen
dc.subjectHead and Neck Canceren
dc.subjectSquamous Cell Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAnoxia-
dc.subject.meshCell Line, Tumor-
dc.subject.meshDisease-Free Survival-
dc.subject.meshFemale-
dc.subject.meshGene Expression Regulation, Neoplastic-
dc.subject.meshHead and Neck Neoplasms-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMicroRNAs-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms, Squamous Cell-
dc.subject.meshPrognosis-
dc.subject.meshRNA Precursors-
dc.subject.meshTumor Markers, Biological-
dc.titlehsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.en
dc.identifier.journalCanceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.